




- (51) International Patent Classification:
C12Q 1/6886 (2018.01) G16H 50/20 (2018.01)
- (21) International Application Number:
PCT/US2024/015444
- (22) International Filing Date:
12 February 2024 (12.02.2024)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/445,284 13 February 2023 (13.02.2023) US
63/470,101 31 May 2023 (31.05.2023) US
63/528,237 21 July 2023 (21.07.2023) US
- (71) Applicant: DELFI DIAGNOSTICS, INC. [US/US]; 2809 Boston Street, Suite 503, Baltimore, Maryland 21224 (US).
- (72) Inventors: SKIDMORE, Zachary L.; c/o DELFI DIAGNOSTICS, INC., 2809 Boston Street, Suite 503, BALTIMORE, Maryland 21224 (US). RINALDI, Lorenzo; c/o DELFI DIAGNOSTICS, INC., 2809 Boston Street, Suite 503, Baltimore, Maryland 21224 (US).
- (74) Agent: HAILE, Lisa A. et al.; DLA PIPER LLP US, 4365 Executive Drive, Suite 1100, SAN DIEGO, California 92121-2133 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: DELFI-DERIVED CELL-FREE DNA FRAGMENTATION PATTERNS DIFFERENTIATE HISTOLOGIC SUBTYPES OF LUNG CANCERS IN A NON-INVASIVE MANNER

FIGURE 1



(57) Abstract: The present disclosure provides methods of uses thereof for improved diagnostic applications using genome-wide patterns of fragmented cell-free DNA (cfDNA) from plasma, derived by low-coverage whole-genome sequencing. In particular, the present invention provides new and effective methods for subtyping non-small cell lung cancer in a subject as low neuroendocrine or high neuroendocrine non-small cell lung cancer.